SecBot SecBot
Biotech Drug Report Generated Nov 16, 2026

S4V2

VALN·Valneva SE
NEUTRAL
Drug Impact Rating3/10
Trial phase
Phase 2
Time to market
At least 4-6 years away. The vaccine is in Phase 2 with no Phase 3 trial started or announced. Valneva is still evaluating next steps after the November 2026 readout. A pivotal Phase 3 program, if initiated, would take several years to complete before any regulatory filing.
Why 3/10
No hard dated binary catalyst is scheduled in the next ~12 months. The Phase 2 readout already occurred on November 9, 2026. The next catalyst would be Valneva's decision on a Phase 3 path, but no date has been set. S4V2 is one of several pipeline assets at Valneva (alongside approved IXCHIQ, Pfizer-partnered Lyme vaccine, and marketed travel vaccines), so it is not a single-asset binary. Impact score is 3: a mid-stage drug with no imminent pivotal readout or PDUFA.
Actionable Insight NEUTRAL

S4V2's positive Phase 2 readout is already public and priced into the stock to some degree (VALN rose ~5% on the news). The next meaningful catalyst is Valneva's decision on whether and how to advance S4V2 into Phase 3, which could come alongside the November 24, 2026 nine-month results or at a later R&D day. For now, S4V2 is a long-duration pipeline option with no near-term binary event; Valneva's stock will be driven more by IXCHIQ commercial traction, the Pfizer-partnered Lyme vaccine's regulatory progress, and the company's cash runway.

Price Chart

Loading chart...

Executive Summary

S4V2 is Valneva's tetravalent (four-strain) bioconjugate vaccine candidate against shigellosis, a severe diarrheal disease with no approved vaccine. On November 9, 2026, Valneva and partner LimmaTech reported positive Phase 2 results from both a controlled human infection model in US adults (met primary endpoint) and an infant safety/immunogenicity trial in Kenya (immune responses against all four serotypes). The FDA granted Fast Track designation in 2024. Valneva is now evaluating next steps, with no Phase 3 trial or regulatory filing announced. S4V2 is a promising but early-stage asset in a pipeline that also includes the approved chikungunya vaccine IXCHIQ, a Pfizer-partnered Lyme vaccine, and marketed travel vaccines. The stock (VALN) trades near $5.66 with a ~$562M market cap.

How It Works

S4V2 is a tetravalent (four-strain) bioconjugate vaccine designed to protect against shigellosis, a bacterial infection that causes severe diarrhea and is the second leading cause of fatal diarrheal disease worldwide, especially in young children in developing countries. It works by training the immune system to recognize and fight four different strains of Shigella bacteria simultaneously. No vaccine for shigellosis is currently approved anywhere in the world.

Trial Status

Valneva and partner LimmaTech Biologics announced positive results from two Phase 2 trials on November 9, 2026. A controlled human infection model (CHIM) trial in US adults met its primary endpoint with a statistically significant reduction in shigellosis incidence. A separate infant immunogenicity and safety trial in Kenyan infants showed statistically significant immune responses against all four Shigella serotypes with a favorable safety profile. The company is evaluating the full dataset to determine the next development path.

The Two-Sided Case

▲ Bull Case4
S4V2 is the world's most clinically advanced tetravalent bioconjugate vaccine candidate against shigellosis, a disease with no approved vaccine and high unmet need globally
Phase 2 results were positive across both adult CHIM (efficacy signal) and infant (immunogenicity/safety) trials simultaneously, de-risking the program significantly
FDA granted Fast Track designation in October 2024, which can accelerate development and review
Valneva's partner LimmaTech brings specialized bioconjugate platform expertise; AGC Biologics is contracted for drug substance supply
▼ Bear Case5
No Phase 3 trial has been initiated or even formally designed; Valneva is still evaluating the development path, meaning meaningful clinical data is years away
Valneva faces significant financial constraints: the company cut its 2026 revenue outlook and workforce after Q1 sales dropped 40%, and the stock trades near its 52-week low of $4.75
S4V2 is a small part of Valneva's pipeline; the company's near-term value drivers are the Pfizer-partnered Lyme vaccine (VLA15) and the approved IXCHIQ chikungunya vaccine, not S4V2
Shigella vaccine development has historically been challenging; no candidate has reached approval despite decades of effort
Valneva voluntarily withdrew its US applications for IXCHIQ in January 2026, signaling regulatory headwinds in the US market

Upcoming Catalysts

  • Valneva's decision on the Phase 3 development path and timeline for S4V2 (no date set)
  • Nine-month 2026 financial results on November 24, 2026 (may include pipeline update)

Source Filing

The SecBot filing or press-release report that triggered this drug report:

Valneva SE 6-K VALN ·Originating report

Sources · 9

Hover a chip for the title
1 msn.com2 rttnews.com3 marketscreener.com4 ad-hoc-news.de5 sec.gov6 ideal-investisseur.fr7 fox5sandiego.com8 businesswire.com9 ad-hoc-news.de